The list of international projects SAS
Biomedical Research Center SAS
A4L_BRIDGE The role and mutational profile of immune checkpoint molecules in hematologic malignancies
A4L_BRIDGE Úloha a mutačný profil imunitných kontrolných bodov v hematologických nádoroch
A4L_BRIDGE Expression of immune genes in human skin non-immune cells affected by TBEV infection
A4L_BRIDGE Expresia imunitných génov v neimunitných bunkách ľudskej kože ovplyvnených infekciou TBEV
| Duration: |
1.11.2024 - 31.10.2025 |
| Program: |
Other |
| Project leader: |
Mgr. Štibrániová Iveta PhD. |
| Annotation: | The tick, host and pathogen form an interactive triangle in which the host's skin is the site of first contact. Despite its effective barrier function, the skin is still the main entry point for most tick-borne pathogens, including tick-borne encephalitis virus (TBEV). TBEV enters the skin through the saliva of infected ticks during feeding. TBEV targets resident skin cells, resulting in an antiviral response activated by viral RNA. Through immunomodulation, tick saliva promotes TBEV replication at the tick feeding site. One of the most abundant non-immune cells of the skin - keratinocytes - not only represent a potential reservoir of TBEV, but are also capable of eliciting an immune response to TBEV that may influence its distribution to target organs. Skin keratinocytes will be treated with TBEV (Hypr) or salivary gland extracts (SGE) from uninfected and TBEV (Hypr) infected ticks of two species, Ixodes ricinus and Dermacentor reticulatus. Using mRNA-seq, we want to identify the expression of genes associated with innate antiviral responses of TBEV-infected human skin keratinocytes and to elucidate the potential influence of bioactive compounds in the SGE of TBEV-infected ticks on this expression. Transcriptional profiling of SGE-treated cells from TBEV-free ticks compared to TBEV-infected SGE-treated cells, obtained within this study would also provide a comprehensive picture of how tick feeding affects the local environment over time. |
A4L_BRIDGE Identification of TGF-β 1 binding molecule(s) in saliva of adult ticks Dermacentor reticulatus
A4L_BRIDGE Identifikácia molekúl viažúcich TGF-β 1 v slinách dospelých kliešťov Dermacentor reticulatus
| Duration: |
1.11.2024 - 31.10.2025 |
| Program: |
Other |
| Project leader: |
Mgr. Bartíková Pavlína PhD. |
| Annotation: | Ticks are successful vectors of the broadest spectrum of pathogens due to their unique features – hematophagy, extended feeding periods (up to weeks), prolonged life-span and complex development, and blood digestion within midgut cells. Their parasitic lifestyle resulted in development of a broad spectrum of evasive and disarming mechanisms of host defense reactions. Tick saliva is a mixture of proteins, peptides and non-peptide molecules that interfere with various components of hemostasis, wound healing, and host immune system. Additionally, some of these bioactive molecules have a promising therapeutic perspective to cure some human diseases associated with dysregulation of specific cytokines/growth factors and alterations in their signaling pathways. According to the ability of tick saliva to bind a human growth factor TGF-β1, in a previous project we tried to identify these molecule(s) using a pull-down purification with coupled biotinylated TGF-β1 followed by LC-MS (timsTOF Pro) analyses. However, purified samples were still very rich on protein content, up to 967 (female ticks) or 617 protein groups (male ticks), respectively. Thus, combination of these two methods was not very effective and the identification of TGF-β1 binding molecule(s) is still undergoing. Prior LC-MS/MS analyses, we plan to combine more purification methods (NGC chromatography, IEF-PAGE and Western-blot) to reduce the number of protein groups in samples. |
Alliance4Life Bridging the Research and Innovation Gap in Life Sciences
Alliance4Life Preklenutie výskumnej a inovačnej priepasti v živých vedách
| Duration: |
1.3.2024 - 29.2.2028 |
| Program: |
Horizon Europe |
| Project leader: |
prof. RNDr. Pastoreková Silvia DrSc. |
| Annotation: | The persisting R&I gap between Western and Eastern Europe is a major challenge to the EU. It includes under-developed R&I ecosystems, a lower ability to attract and retain talents, single-track research careers with a lack of modern HR, and fragmented industry-academia collaboration. To improve the situation in Central and Eastern Europe (CEE), Alliance for Life Sciences (Alliance4Life) was formed by 12 progressive health research institutions and universities in 11 CEE countries. Since 2018 it has become a lively community and role model of modern institutional governance and excellent research in CEE, piloted strategic institutional reforms, and succeeded in influencing national R&I reforms and EU policy. With the A4L_BRIDGE project, the alliance focuses on a broader implementation of the successfully piloted strategic changes toward enhanced attractiveness, competitiveness, and innovation strength, and newly also addresses excellence in higher education. The scientific collaboration will be boosted by a Virtual Research Centre, connecting different research groups, and thanks to seed funding, initial research projects with IP originating in CEE will be prepared to be developed into RIA projects for Horizon Europe. The alliance will develop a complex educational matrix, including mentoring, e-learning, and international internships, targeting both academic and non-academic staff in all career stages. The Industry Relationship Platform will stimulate knowledge transfer and partaking in applied research projects. Societal actors will be invited to shape the research agendas and will be addressed at events for end users of health research results. Events, webinars, and dissemination activities will target national stakeholders and policymakers, promoting ERA values and supporting the empowering of low-performing regions in their R&I upscale. The A4L_BRIDGE project will thus significantly contribute to bridging the gap in R&I performance in the EU. |
Alzheimer's Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe
Alzheimerova choroba: Diagnostika, inovácie a translácia do klinickej praxe v strednej Európe
| Duration: |
1.1.2023 - 31.12.2026 |
| Program: |
Horizon Europe |
| Project leader: |
prof. MUDr. Ukropcová Barbara PhD. |
| Annotation: | Alzheimer’s disease (AD) affects millions of individuals worldwide, and currently there are no effective disease-modifying therapies. Prompt AD diagnosis is beneficial with respect to care and delay of disease progression. However, the implementation of modern AD diagnostics in clinical practice in Czechia and Slovakia is fragmented. To address this, the EU-funded ADDIT-CE project will support the cooperation between academia, business, government and civil society. The partnership is expected to strengthen research and innovation in the field of AD diagnostics and introduce novel technologies into AD clinical management. ADDIT-CE will help design a national plan for combatting dementia and establish a functional innovation ecosystem that will revolutionise diagnostic approaches and continue to serve society even after the project’s completion. |
European Network for Skin Engineering and Modeling
Európska sieť pre kožné inžinierstvo a modelovanie
European Network for Sigma-1 Receptor as a Therapeutic Opportunity
Európske konzorcium pre Sigma-1 receptor ako terapeutický cieľ
| Duration: |
25.10.2024 - 24.10.2028 |
| Program: |
COST |
| Project leader: |
RNDr. Cagalinec Michal PhD. |
| Annotation: | The sigma-1 receptor (S1R) is a ligand-regulated endoplasmic reticulum chaperone protein and a target for innovative compounds for the treatment of neurodegenerative and inflammatory diseases, cancers and pain diseases. The SIGMA-1 EUROPE network will bring together disciplines and expertises across Europe to advance the exploration and identification of the role of the Sigma-1 receptor in physiology and pathologies, to design innovative S1R ligands for cellular biology and medicine, and ultimately to train young researchers and innovators to revise our views of the diseases, to think out-of-the-box and explore novel and innovative
therapeutic opportunities. |
European partnership fostering a European Research Area (ERA) for health research
Európske partnerstvo prehlbujúce spoluprácu v rámci Európskeho výskumného priestoru (ERA) pre zdravotnícky výskumu
| Duration: |
1.11.2022 - 30.10.2029 |
| Program: |
Horizon Europe |
| Project leader: |
doc. MUDr. Imrich Richard DrSc. |
| Annotation: | Excellent EU programs push health R&I but are not sufficient. Synergy with strategic initiatives in MS and a new model for impactful collaborations are needed to address the challenges for health. ERA4Health brings the opportunity to increase EU transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing EU Public Health Needs, with total duration of 7 years. ERA4Health focuses on tackling diseases and reducing disease burden and the following challenges: 1) the increasing demand for a better quality of life and a better care of patients, 2) the need to transform public health care systems in more effective, efficient, equitable, accessible, and resilient ones and 3) the need to strengthen disease prevention and health promotion. In this view, ERA4Health objectives are: .SO1- Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment) .SO2- Improve the utilisation of existing health technologies in clinical practice .SO3- Build capacity, in particular in conducting Investigator Initiated Clinical Studies at EU scale .SO4- Implement and advance the practice of RRI across the breadth of the programme ERA4Heatlth will be implemented in 2 phases: . Phase 1 (2 years) will implement joint calls focused on nutrition and lifestyle-related diseases, cardiovascular diseases and nanomedicine (4 in two years). In parallel, it will establish a supporting framework to overcome the challenges in launching international IICSs joint calls. . Phase 2, if the EC approves it: additional multinational calls for IICSs and joint calls for other priority areas will be launched in accordance with the decision of the Health Programme Committee taken at the end of previous Phase 34 partners (20 from EU, 3 Third Countries associated to HE and 2 non-associated, non EU), will commit 90,510,000€, during the 3 first years, as financial support to third parties. |
Genomic instability in cells from persons exposed to RF from base stations
Genomická nestabilita v bunkách od osôb vystavených RF zo základných staníc
| Duration: |
8.9.2021 - 31.12.2027 |
| Program: |
Other |
| Project leader: |
doc. Ing. Beliaev Igor DrSc. |
| Annotation: | The blood samples from persons exposed to radiofrequency radiation (RF) from base stations will be analyzed for DNA damage and genetic instability using comprehensive techniques and endpoints including oxidative damage, comet assay, chromosomal aberrations, micronuclei assay, preleukemic gene fusions. The data will be correlated with RF exposures provided by the German partner. |
Identification of biological markers for prevention and translational medicine in pancreatic cancer
Identifikácia biologických markerov pre prevenciu a translačnú medicínu pri rakovine pankreasu
| Duration: |
11.10.2022 - 10.10.2026 |
| Program: |
COST |
| Project leader: |
Mgr. Smolková Božena PhD. |
| Annotation: | Pancreatic cancer (PC) has a high mortality rate and is projected to become a massive public health problem in Europe. This Action will boost research on prevention of PC, particularly in the discovery of genetic risk factors, risk stratification, identification of biomarkers for early detection and patient monitoring, elucidation of biological mechanisms and functional pharmacogenomics for personalized medicine. These aims will be attained by expanding an existing interdisciplinary network.
The Action will be organized in the following working groups:
• Disease risk profiling. This WG will use germline genetic variants, epigenetics, transcriptomics and environmental factors to model disease risk and apply risk stratification scores to better select individuals eligible to be screened for PC or its precursors.
• Non-invasive biomarkers. This WG will apply state-of-the-art liquid biopsies for the detection and characterization of circulating tumor cells and DNA, tumor-derived exosomes, tumor-educated platelets, epigenetic markers, and will test their diagnostic value for PC precursors and early-stage PC.
• Tumor profiling. Genomic, epigenomic and transcriptional profiling of PC and its precursors in a multiregional analysis fashion will be used to identify novel biomarkers with prognosis and predictive value for PC patient stratification.
• Functional genomics and therapy. This WG will functionally validate candidate genetic variants from germline or tumor studies by using cutting-edge approaches such as CRISPR-Cas9 gene editing. It will also generate novel approaches such as organoids / zebrafish avatars to implement (chemo)therapeutic strategies based on the patient in an effort to implement personalized medicine for PC. |
Information, Coding, and Biological Function: the Dynamics of Life
Informácia, kódovanie a biologická funkcia: Dynamika života
| Duration: |
2.10.2023 - 18.9.2026 |
| Program: |
COST |
| Project leader: |
RNDr. Farkaš Robert CSc. |
| Annotation: | The previous and current work of our group focuses on the mechanistic aspects of apocrine secretion (AS), a novel and previously incorrectly described type of non-canonical and non-vesicular transport and secretory mechanism. We discovered AS by serendipity in salivary glands of Drosophila, a well defined genetic model organism. Our long-term goal is to decipher molecular and genetic aspects of AS using tools so uniquely available in the fruitfly. As we already found, AS is phylogenetically conserved, and it is present in all eukaryotic metazoans, including human. In addition, AS is implicated also in at least two dozen of human disorders. Material released by AS is considerably enriched in proteins (proteomics identified >1500 entities), and this liquid “soup” contains highly viable or zymogen-like dormant proteins capable of immediate activation upon challenge. All these aspects make phenomenon of apocrine secretion very dynamic biological system. Currently, we are the only research group in the world that deals with elementary molecular-genetic and structural aspects of apocrine secretion per se. |
Integrated Services for Infectious Disease Outbreak Research
Integrované služby pre výskum prepuknutia infekčných chorôb
Reward-stress interactions as neurobiological substrate for resilience and vulnerability in mental health and depression: A translational large-scale project
Interakcia medzi odmenou a stresom ako neurobiologický podklad odolnosti a rezistencie v duševnom zdraví a depresii: Rozsiahly translačný projekt
COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
KOMPLEXNÉ ONKOLOGICKÉ INFRAŠTRUKTÚTY 4 EUROPE
Translational control in Cancer European Network
Kontrola translácie v Cancer European Network
Genome Editing to Treat Humans Diseases
Liečba chorôb modifikáciou genómu
International networking on in vitro colon models simulating gut microbiota mediated interactions
Medzinárodná sieť zameraná na in vitro modely hrubého čreva simulujúce interakcie sprostredkované črevnou mikrobiotou
Modelling immunotherapy response and toxicity in cancer
Modelovanie toxicity a odpovede na imunoterapiu pri liečbe rakoviny
| Duration: |
2.11.2022 - 1.11.2026 |
| Program: |
COST |
| Project leader: |
Mgr. Smolková Božena PhD. |
| Annotation: | The IMMUNO-model COST Action aims to foster research and innovation in the field of preclinical immuno-oncology models with the ultimate goal of advancing in the treatment of cancer patients by improving their outcomes and quality of life. The unprecedented change that immunotherapy has represented in the treatment of cancer is best illustrated by the spectacular results obtained in previously incurable malignancies, such as metastatic melanoma. However, the widespread use of these therapies has been hindered by their limited effectiveness and associated toxicities. A better understanding on the complex interactions between tumor cells and the immune system is strictly required to address these problems, and to develop more effective and safer immunotherapies. However, one of the most important obstacles in immuno-oncology research is the scarcity of preclinical models that faithfully recapitulate human immunity and contribute to identify novel therapeutic targets, characterize biomarkers of therapeutic response and toxicity, and generate reliable data on drug synergies. IMMUNO-model will bring together European researchers from diverse sectors (academia, clinical, industry) with the common goal of establishing a Network that endorses immuno-oncology research by specifically promoting the sharing, standardization and application of immunotherapy preclinical models. |
Nanobiotechnologies for Innovative Therapeutic Approaches for Cancer
Nanotechnológie pre inovatívne terapeutické prístupy pre rakovinu
| Duration: |
1.11.2023 - 31.10.2028 |
| Program: |
Horizon Europe |
| Project leader: |
RNDr. Matúšková Miroslava PhD. |
| Annotation: | NANOBIO4CAN is a new collaborative research & training programme of excellence for the recruitment of 24 postdoctoral fellows in the field of cancer nanomedecine It is led by Sabanci University Nanotechnology Research and Application Center (SUNUM) in collaboration with 3 leading Turkish research centers in life sciences: TUBITAK Marmara Research Center (TUBITAK-MAM), Koç University Research Center for Translational Medicine (KUTTAM) and Izmir Biomedicine and Genome Center (IBG). The overarching objective of the programme is to enhance the potential and future career perspectives of recruited postdoctoral fellows by providing a highly interdisciplinary & intersectoral research approach in nanobiotechnology & cancer research while maintaining the highest research quality standards and fulfilling all the principles of Open Science. The programme will also further strengthen the collaborative approach of the beneficiary and implementing participating entities by consolidating their excellence and outstanding track-record and providing the ideal setting for prospective postdoctoral researchers in the programme’s research priorities |
Precision medicine in biliary tract cancer
Presná medicína pri rakovine žlčových ciest
Prevention, anticipation and mitigation of tick-borne disease risk applying the DAMA protocol
Prevencia, predvídanie a zmierňovanie rizika ochorenia prenášaného kliešťami pomocou protokolu DAMA
| Duration: |
18.10.2022 - 17.10.2026 |
| Program: |
COST |
| Project leader: |
Mgr. Špitalská Eva PhD. |
| Annotation: | Emerging infectious diseases (EIDs) represent a national security threat for every country, exacerbated by climate change, human population expansion, urbanization, and globalization. Based on theoretical expectations previously EIDs were thought to be rare and impossible to anticipate because they require novel genetic mutations to infect novel hosts. A new conceptual framework has been developing for nearly 40 years and has recently been articulated in a manner that leads directly to a protocol for taking proactive or anticipatory steps in coping with EIDs, especially those numerous high probability/low impact pathogens. The framework is called the Stockholm paradigm, which shows that a major trigger of emerging disease, now and in the past, has been climate change. The PRAGMATICK COST action aims to disseminate knowledge and promote the application of the Stockholm paradigm in order to anticipate and mitigate disease risk associated with the presence and spread of ticks and tick-borne pathogens (TBPs) under anthropogenic pressure and changing climate. This research network will apply the comprehensive and highly focused DAMA (Document, Assess, Monitor, Act) protocol that allows to “anticipate to mitigate” emerging diseases. The main focus is on urban tick and TBP hotspots and the spread and establishment of ticks and TBPs. PRAGMATICK will find new ticks and tick-borne pathogens before they find us. By applying citizen science and supporting capacity building in the domain of tick and tick-borne disease prevention, the Action will eventually lead to new and improved insights in the potential threats related to this important group of vectors across Europe. |
Prevention, anticipation and mitigation of tick-borne disease risk applying the DAMA protocol
Prevencia, predvídanie a zmierňovanie rizika ochorenia prenášaného kliešťami pomocou protokolu DAMA
| Duration: |
18.10.2022 - 17.10.2026 |
| Program: |
COST |
| Project leader: |
RNDr. Minichová Lenka PhD. |
| Annotation: | Emerging infectious diseases (EIDs) represent a national security threat for every country, exacerbated by climate change, human population expansion, urbanization, and globalization. Based on theoretical expectations previously EIDs were thought to be rare and impossible to anticipate because they require novel genetic mutations to infect novel hosts. A new conceptual framework has been developing for nearly 40 years and has recently been articulated in a manner that leads directly to a protocol for taking proactive or anticipatory steps in coping with EIDs, especially those numerous high probability/low impact pathogens. The framework is called the Stockholm paradigm, which shows that a major trigger of emerging disease, now and in the past, has been climate change. The PRAGMATICK COST action aims to disseminate knowledge and promote the application of the Stockholm paradigm in order to anticipate and mitigate disease risk associated with the presence and spread of ticks and tick-borne pathogens (TBPs) under anthropogenic pressure and changing climate. This research network will apply the comprehensive and highly focused DAMA (Document, Assess, Monitor, Act) protocol that allows to “anticipate to mitigate” emerging diseases. The main focus is on urban tick and TBP hotspots and the spread and establishment of ticks and TBPs. PRAGMATICK will find new ticks and tick-borne pathogens before they find us. By applying citizen science and supporting capacity building in the domain of tick and tick-borne disease prevention, the Action will eventually lead to new and improved insights in the potential threats related to this important group of vectors across Europe. |
Role of the CA IX ectodomain in tumor growth and metastasis
Úloha ektodomény CA IX v nádorovom raste a metastázovaní
| Duration: |
11.11.2014 - 31.12.2025 |
| Program: |
Other |
| Project leader: |
prof. RNDr. Pastoreková Silvia DrSc. |
| Annotation: | This project is aimed at understanding the role of the CA IX ECD in tumor growth and metastasis in vivo using mouse models. We intend to evaluate growth of tumor xenografts (following subcutaneous implantation of tumor cells) and colonization of lungs (following injection of tumor cells into the tail vein) in absence and presence of the recombinant CA IX ECD. In addition, we plan to evaluate potential therapeutic targeting of CA IX ECD through analysis of the anticancer effect of antibodies binding to different regions of the ectodomain, including M75 and VII/20. Particularly M75 is of great interest, because the N-terminal PG region, to which M75 binds, was recently found to be involved in cell adhesion and spreading, the processes contributing to metastatic dissemination. On the other hand, MAb VII/20 binds to the central CA catalytic domain and was previously shown to reduce the growth of primary tumors, but its effect on metastasis has not been examined so far.
Thus, we expect that the project will allow us to dissect the role of ECD in metastasis and propose antibody-based therapeutic strategies to reduce metastatic growth.
|
The role of Adipose tissue and muscle crosstalk in the regulation of METabolic flexibility: exploration of novel predictors of the lifestyle Intervention Success in patients with obesity
Úloha tukového tkaniva a svalov v regulácii metabolickej flexibility: Skúmanie nových prediktorov úspešnej intervencie do životného štýlu obéznych pacientov
Early detection of esophageal squamous cell carcinoma with the Cytosponge coupled with molecular biomarkers and machine learning
Včasná detekcia spinocelulárneho karcinómu pažeráka pomocou Cytosponge v spojení s molekulárnymi biomarkermi a strojovým učením
Wildlife Malaria Network
Výskum malárie voľne žijúcich zvierat
| Duration: |
28.9.2023 - 27.9.2027 |
| Program: |
COST |
| Project leader: |
RNDr. Minichová Lenka PhD. |
| Annotation: | Vector-borne diseases, and emerging infectious diseases of wildlife, are major contributors to the global disease burden and of increasing concern globally. Haemosporidian parasites are ubiquitous in nature, hugely diverse, and associated with morbidity and mortality across taxa, including humans, livestock and wildlife. Many research groups globally focus on these parasites as model systems for addressing a broad range of ecological and evolutionary questions with economic and health implications. This Action will bring together individuals and research groups to focus on coordinating research objectives to which multiple groups can contribute existing datasets, meaning that questions can be addressed at a global, rather than a local or regional, scale. Ornithologists, mammologists and herpetologists have a long history of investigating haemosporidian parasites in natural populations; these studies have provided insights into host-parasite associations, parasite geographic distributions, host-switching and the context-dependence of host-parasite relationships, alongside pathogenic impacts and conservation implications of haemosporidian infections. Increasingly, research groups are investigating the vectors of these parasites, and utilising novel genetic techniques to understand parasite gene expression, among many other examples. Coordinating and sharing research efforts between groups offers huge potential for large-scale collaborative research initiatives. This Action will promote the development of a common research agenda by providing opportunities for training, collaboration and knowledge exchange, targeting diverse researchers across disciplines to foster an interdisciplinary approach, whilst also recruiting and supporting a diversity of new researchers. The Action will target stakeholders, policymakers and the general public to endorse knowledge transfer and maximise the reach of the network. |
Investigation of selected triorganotin compounds potentially acting as nuclear retinoid X receptor ligands in breast cancer derived cell lines by in silico and in vitro approaches
Výskum vybraných triorganocíničitých zlúčenín potenciálne účinkujúcich ako ligandy nukleárnych retinoidných X receptorov v ľudských karcinómoch prsníka pomocou in silico a in vitro metodologických prístupov
Zoonoses Emergence across Degraded and Restored Forest Ecosystems
Vznik zoonóz v poškodených a obnovených lesných ekosystémoch
| Duration: |
1.1.2024 - 31.12.2027 |
| Program: |
Horizon Europe |
| Project leader: |
RNDr. Klempa Boris DrSc. |
| Annotation: | Ecosystem degradation and biodiversity loss may facilitate the emergence of zoonotic diseases. The 4-year ZOE project will analyze the links between landcover and land use changes in tropical biodiversity hot-spots facing loss of primary forest and biodiversity and in temperate regions that have undergone ecosystem degradation and deforestation over historical timescales. In areas experiencing different levels of ecosystem degradation, biodiversity assessments will be based on remote sensing-based GIS analysis of landscape structures, geobotanic plant mapping, and targeted trapping of rodents, ticks, and mosquitoes, as prototypic reservoirs and vectors of zoonotic diseases (macro-organism scale). Host and soil-associated microbiome and virome high-throughput sequencing will be combined with assessment of human exposure to prototypic zoonotic pathogens, using high-throughput serological analyses (microbiological scale). ZOE will link with local communities and stakeholders to address perceived land use and land cover changes, disease occurrence, coping strategies, and risk behaviour. Results will be synthesized in modelling and risk mapping frameworks linking biodiversity loss and zoonotic disease risks and tested in forecasting scenarios to feed into cost-efficient monitoring schemes and early warning systems. An online knowledge platform will be created to link all relevant stakeholders of the biodiversity-health nexus, including other EU-funded consortia, national and supranational organizations stakeholders, local communities, and the public. A joint stakeholder conference will be organized, and community engagement workshops will specifically co-create and advance knowledge in local communities involved in ZOE. The ZOE project is proposed by an interdisciplinary consortium with expertise in geography, geobotanics, ecology, virology, immunology, epidemiology, sociology, psychology, anthropology and science dissemination from 7 EU and 4 American countries. |
A sound proteome for a sound body: targeting proteolysis for proteome remodeling
Zdravý proteóm pre zdravé telo: zacielenie proteolýzy na remodeláciu proteómu
| Duration: |
1.11.2023 - 6.10.2025 |
| Program: |
COST |
| Project leader: |
RNDr. Farkaš Robert CSc. |
| Annotation: | Our work focuses on the mechanistic aspects of apocrine secretion (AS), a novel and previously incorrectly described type of non-canonical and non-vesicular transport and secretory mechanism. As we discovered apocrine secretion in Drosophila, well defined genetic model organism, we are pursuing research aimed at deciphering its molecular and genetic aspects using tools so uniquely available in the fruitfly. AS is evolutionarily conserved, and can be found in all eukaryotic metazoans. Material released by apocrine secretion is considerably enriched in proteins (>1500 entities), and this liquid soup contains highly viable or zymogen-like dormant proteins capable of immediate activation upon challenge. Numerous of these proteins are proteases and their regulators/inhibitors. The main function we described for this secretion is a first defense line in immune response, where these proteases become rapidly activated in action against microorganisms or other antigens. Moreover, AS is implicated also in at least two dozen of human disorders. |
Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer
Zvrátenie epitranskriptomických zmien pre chemosenzibilizáciu nádorov pankreasu
The total number of projects: 30
